Literature DB >> 27101755

The time of resolution and the rate of recurrence in acute central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy: a case-control study.

A Ozkaya1, Z Alkin1, M Ozveren1, A T Yazici1, M Taskapili1.   

Abstract

PurposeTo evaluate the resolution time and the recurrence rate of acute central serous chorioretinopathy (CSC) after spontaneous resolution and low-fluence photodynamic therapy (PDT).MethodsCase-control study: The CSC patients who were admitted to our clinic for the first time were included. No treatment was given during the first 6 months. Patients were treated with PDT after 6 months from the initial signs of the disease, if they did not show any sign of resolution. The patients who showed a significant decrease in subretinal fluid after month 6 were not scheduled for PDT. The primary outcomes were the resolution time and the recurrence rate after the first episode. Secondary outcome measures were the change in BCVA and CRT during the follow up.ResultsA total of 77 consecutive eyes of 77 patients were included, 41 eyes (53.2%) with spontaneously resolved CSC and 36 eyes (46.8%) with PDT-treated CSC. The initial resolution time was 4.1±3.2 months in spontaneous resolution group, and 8.1±0.8 months in PDT group, respectively (P<0.001). The recurrence rate was 51.2% in spontaneous resolution group, and 25% in PDT group (P=0.01). The change in BCVA from baseline to the last follow-up visit was statistically significant in both groups (P=0.002, P=0.003, respectively). The change in CRT from baseline to the last follow up was also statistically significant in both groups (P=0.002, P=0.003, respectively).ConclusionsThe recurrence rate of acute CSC was lower in PDT-treated patients than the spontaneously resolved patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27101755      PMCID: PMC4941077          DOI: 10.1038/eye.2016.79

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  21 in total

1.  Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Kyoko Fujita; Kei Shinoda; Yutaka Imamura; Celso Soiti Matsumoto; Yoshihiro Mizutani; Atsushi Mizota; Mitsuko Yuzawa
Journal:  Am J Ophthalmol       Date:  2012-07-20       Impact factor: 5.258

2.  Retinal and choroidal changes observed with 'En face' enhanced-depth imaging OCT in central serous chorioretinopathy.

Authors:  Mathieu Lehmann; Benjamin Wolff; Vivien Vasseur; Virginie Martinet; Nadine Manasseh; José Alain Sahel; Martine Mauget-Faÿsse
Journal:  Br J Ophthalmol       Date:  2013-07-03       Impact factor: 4.638

3.  Alterations of retinal pigment epithelium in central serous chorioretinopathy.

Authors:  Yasuhiko Hirami; Akitaka Tsujikawa; Manabu Sasahara; Norimoto Gotoh; Hiroshi Tamura; Atsushi Otani; Michiko Mandai; Nagahisa Yoshimura
Journal:  Clin Exp Ophthalmol       Date:  2007-04       Impact factor: 4.207

4.  Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.

Authors:  Yong-Kyu Kim; Na-Kyung Ryoo; Se Joon Woo; Kyu Hyung Park
Journal:  Am J Ophthalmol       Date:  2015-04-14       Impact factor: 5.258

5.  Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy.

Authors:  N H Kang; Y T Kim
Journal:  Eye (Lond)       Date:  2013-01-04       Impact factor: 3.775

6.  Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.

Authors:  Michele Reibaldi; Nicola Cardascia; Antonio Longo; Claudio Furino; Teresio Avitabile; Salvatore Faro; Marisa Sanfilippo; Andrea Russo; Maurizio Giacinto Uva; Ferdinando Munno; Vincenzo Cannemi; Marco Zagari; Francesco Boscia
Journal:  Am J Ophthalmol       Date:  2009-11-06       Impact factor: 5.258

Review 7.  Photodynamic therapy for central serous chorioretinopathy.

Authors:  O C Erikitola; R Crosby-Nwaobi; A J Lotery; S Sivaprasad
Journal:  Eye (Lond)       Date:  2014-06-20       Impact factor: 3.775

8.  Pachychoroid pigment epitheliopathy.

Authors:  David J Warrow; Quan V Hoang; K Bailey Freund
Journal:  Retina       Date:  2013-09       Impact factor: 4.256

9.  Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.

Authors:  Sang-Uk Park; Seung-Jun Lee; Moosang Kim
Journal:  Korean J Ophthalmol       Date:  2014-07-22

10.  Morphologic changes in acute central serous chorioretinopathy using spectral domain optical coherence tomography.

Authors:  Hyung Chan Kim; Won Bin Cho; Hyewon Chung
Journal:  Korean J Ophthalmol       Date:  2012-09-24
View more
  11 in total

1.  OCT biomarkers related to subthreshold micropulse laser treatment effect in central serous chorioretinopathy.

Authors:  Fang Zheng; Jingliang He; Zhitao Su; Ye Liu; Yufeng Xu; Lei Liu; Panpan Ye
Journal:  BMC Ophthalmol       Date:  2022-06-07       Impact factor: 2.086

2.  Interobserver Agreement of Novel Classification of Central Serous Chorioretinopathy.

Authors:  Niroj K Sahoo; Deepika C Parameshwarappa; Mahima Jhingan; Filippo Tatti; Claudio Iovino; Enrico Peiretti
Journal:  Cureus       Date:  2022-06-14

3.  Effects of Ketoconazole on the Clinical Recovery in Central Serous Chorioretinopathy.

Authors:  Yodpong Chantarasorn; Kochapong Rasmidatta; Itsara Pokawattana; Sukhum Silpa-Archa
Journal:  Clin Ophthalmol       Date:  2022-06-09

4.  The comparison of multimodal imaging findings of central serous chorioretinopathy patients in regard to the early anatomically treatment response to half-fluence photodynamic therapy: a retrospective case-control study.

Authors:  Abdullah Ozkaya; Ruveyde Garip; Zeynep Alkin; Muhittin Taskapili
Journal:  Int J Retina Vitreous       Date:  2017-06-12

5.  Oral Spironolactone versus Conservative Treatment for Non-Resolving Central Serous Chorioretinopathy in Real-Life Practice.

Authors:  Suthasinee Sinawat; Watcharaporn Thongmee; Thuss Sanguansak; Wipada Laovirojjanakul; Supat Sinawat; Yosanan Yospaiboon
Journal:  Clin Ophthalmol       Date:  2020-06-24

6.  Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy.

Authors:  Erhan Yumusak; Nesrin Buyuktortop Gokcinar; Kemal Ornek
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

7.  Risk Factors for Persistent or Recurrent Central Serous Chorioretinopathy.

Authors:  Jia Yu; Gezhi Xu; Qing Chang; Xiaofeng Ye; Lei Li; Chunhui Jiang; Qi Zhao
Journal:  J Ophthalmol       Date:  2019-08-14       Impact factor: 1.909

8.  Risk of Recurrence and Transition to Chronic Disease in Acute Central Serous Chorioretinopathy.

Authors:  Danial Mohabati; Camiel J F Boon; Suzanne Yzer
Journal:  Clin Ophthalmol       Date:  2020-04-29

Review 9.  The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy.

Authors:  Stefano Da Pozzo; Pierluigi Iacono; Alessandro Arrigo; Maurizio Battaglia Parodi
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-29

10.  Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy.

Authors:  Miao Zeng; Xiao Chen; Yanping Song; Chunyan Cai
Journal:  BMC Ophthalmol       Date:  2022-03-08       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.